60 related articles for article (PubMed ID: 2786751)
1. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
Weiner LM; O'Dwyer J; Kitson J; Comis RL; Frankel AE; Bauer RJ; Konrad MS; Groves ES
Cancer Res; 1989 Jul; 49(14):4062-7. PubMed ID: 2786751
[TBL] [Abstract][Full Text] [Related]
2. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.
Hertler AA; Schlossman DM; Borowitz MJ; Poplack DG; Frankel AE
Cancer Immunol Immunother; 1989; 28(1):59-66. PubMed ID: 2783301
[TBL] [Abstract][Full Text] [Related]
3. Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin.
Bjorn MJ; Smith HS; Dairkee SH
Cancer Immunol Immunother; 1988; 26(2):121-4. PubMed ID: 3258792
[TBL] [Abstract][Full Text] [Related]
4. Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice.
Brusa P; Dosio F; Pietribiasi F; Delprino L; Feraiorni P; Mariani M; Bussolati G; Cattel L
Cancer Immunol Immunother; 1992; 35(6):373-80. PubMed ID: 1394342
[TBL] [Abstract][Full Text] [Related]
5. Comparison of blocked and non-blocked ricin-antibody immunotoxins against human gastric carcinoma and colorectal adenocarcinoma cell lines.
Cattel L; Delprino L; Brusa P; Dosio F; Comoglio PM; Prat M
Cancer Immunol Immunother; 1988; 27(3):233-40. PubMed ID: 3263208
[TBL] [Abstract][Full Text] [Related]
6. Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies.
Biteghe FAN; Mungra N; Chalomie NET; Ndong JC; Engohang-Ndong J; Vignaux G; Padayachee E; Naran K; Barth S
Oncotarget; 2020 Sep; 11(38):3531-3557. PubMed ID: 33014289
[TBL] [Abstract][Full Text] [Related]
7. Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells.
Mungra N; Jordaan S; Hlongwane P; Naran K; Chetty S; Barth S
Oncotarget; 2019 Jan; 10(8):897-915. PubMed ID: 30783518
[TBL] [Abstract][Full Text] [Related]
8. Enzymatic Transition States and Drug Design.
Schramm VL
Chem Rev; 2018 Nov; 118(22):11194-11258. PubMed ID: 30335982
[TBL] [Abstract][Full Text] [Related]
9. The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations.
Rust A; Partridge LJ; Davletov B; Hautbergue GM
Toxins (Basel); 2017 Oct; 9(11):. PubMed ID: 29076988
[TBL] [Abstract][Full Text] [Related]
10. Plant Toxin-Based Immunotoxins for Cancer Therapy: A Short Overview.
Polito L; Djemil A; Bortolotti M
Biomedicines; 2016 Jun; 4(2):. PubMed ID: 28536379
[TBL] [Abstract][Full Text] [Related]
11. Advances in anticancer immunotoxin therapy.
Alewine C; Hassan R; Pastan I
Oncologist; 2015 Feb; 20(2):176-85. PubMed ID: 25561510
[TBL] [Abstract][Full Text] [Related]
12. Immunotoxins constructed with ribosome-inactivating proteins and their enhancers: a lethal cocktail with tumor specific efficacy.
Gilabert-Oriol R; Weng A; Mallinckrodt Bv; Melzig MF; Fuchs H; Thakur M
Curr Pharm Des; 2014; 20(42):6584-643. PubMed ID: 25341935
[TBL] [Abstract][Full Text] [Related]
13. The development of immunoconjugates for targeted cancer therapy.
Smaglo BG; Aldeghaither D; Weiner LM
Nat Rev Clin Oncol; 2014 Nov; 11(11):637-48. PubMed ID: 25265912
[TBL] [Abstract][Full Text] [Related]
14. Effects of a second-generation human anti-ErbB2 ImmunoRNase on trastuzumab-resistant tumors and cardiac cells.
D'Avino C; Paciello R; Riccio G; Coppola C; Laccetti P; Maurea N; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2014 Mar; 27(3):83-8. PubMed ID: 24421342
[TBL] [Abstract][Full Text] [Related]
15. A novel fully human antitumor immunoRNase resistant to the RNase inhibitor.
Riccio G; D'Avino C; Raines RT; De Lorenzo C
Protein Eng Des Sel; 2013 Mar; 26(3):243-8. PubMed ID: 23232187
[TBL] [Abstract][Full Text] [Related]
16. Proposed mechanism of off-target toxicity for antibody-drug conjugates driven by mannose receptor uptake.
Gorovits B; Krinos-Fiorotti C
Cancer Immunol Immunother; 2013 Feb; 62(2):217-23. PubMed ID: 23223907
[TBL] [Abstract][Full Text] [Related]
17. Toxin-based therapeutic approaches.
Shapira A; Benhar I
Toxins (Basel); 2010 Nov; 2(11):2519-83. PubMed ID: 22069564
[TBL] [Abstract][Full Text] [Related]
18. A novel fully human antitumour immunoRNase targeting ErbB2-positive tumours.
Borriello M; Laccetti P; Terrazzano G; D'Alessio G; De Lorenzo C
Br J Cancer; 2011 May; 104(11):1716-23. PubMed ID: 21559015
[TBL] [Abstract][Full Text] [Related]
19. A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin.
Castelletti D; Fracasso G; Righetti S; Tridente G; Schnell R; Engert A; Colombatti M
Clin Exp Immunol; 2004 May; 136(2):365-72. PubMed ID: 15086403
[TBL] [Abstract][Full Text] [Related]
20. Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones.
Tommasi M; Castelletti D; Pasti M; Fracasso G; Lorenzetti I; Sartoris S; Pera C; Ferrara GB; Tridente G; Colombatti M
Clin Exp Immunol; 2001 Sep; 125(3):391-400. PubMed ID: 11531946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
